Structures by: Zheng X. L.
Total: 31
C48H44.50N4O20.25S8
C48H44.50N4O20.25S8
Journal of medicinal chemistry (2009) 52, 20 6402-6412
a=12.6727(5)Å b=30.0947(13)Å c=13.5037(6)Å
α=90.00° β=96.832(3)° γ=90.00°
C52H65N4O26.50S4
C52H65N4O26.50S4
Journal of medicinal chemistry (2009) 52, 20 6402-6412
a=13.699(5)Å b=13.796(5)Å c=15.189(6)Å
α=88.402(11)° β=77.838(6)° γ=81.671(10)°
K4.5 Na4 (H3 O)3.5 (Ce (Si W11 O39)2) (H2 O)23
CeH56.5K4.5Na4O104.5Si2W22
Jiegon Huaxue (2001) 20, 413-417
a=16.531Å b=23.193Å c=12.764Å
α=99.74° β=91.9° γ=94.84°
Na10 (La Si W11 O39 (H2 O)4)2 (H2 O)22
H60La2Na10O108Si2W22
Jiegon Huaxue (2001) 20, 451-454
a=17.9786Å b=23.594Å c=13.1289Å
α=90° β=90.141° γ=90°
C72H78Cl3EuN16O13
C72H78Cl3EuN16O13
Dalton Transactions (2009) 12 2157-2169
a=13.31530(10)Å b=23.3369(2)Å c=23.6480(3)Å
α=90.00° β=91.8520(10)° γ=90.00°
C31H37Cl3EuN7O
C31H37Cl3EuN7O
Dalton Transactions (2009) 12 2157-2169
a=12.5760(4)Å b=16.8021(3)Å c=16.3175(4)Å
α=90.00° β=112.530(4)° γ=90.00°
C55H51EuN18O21
C55H51EuN18O21
Dalton Transactions (2009) 12 2157-2169
a=14.0075(2)Å b=21.1128(3)Å c=21.0118(4)Å
α=90.00° β=106.525(2)° γ=90.00°
C118H122Eu2F18N28O22S6
C118H122Eu2F18N28O22S6
Dalton Transactions (2009) 12 2157-2169
a=11.14290(10)Å b=25.0896(3)Å c=24.2409(2)Å
α=90.00° β=96.0310(10)° γ=90.00°
C56H59Cl3N15O13Tb
C56H59Cl3N15O13Tb
Dalton Transactions (2009) 12 2157-2169
a=12.809(5)Å b=21.053(4)Å c=22.626(4)Å
α=90.00° β=90.00° γ=90.00°
C66H75Cl3N13O15Tb
C66H75Cl3N13O15Tb
Dalton Transactions (2009) 12 2157-2169
a=13.730(2)Å b=13.730(2)Å c=32.236(6)Å
α=90.00° β=90.00° γ=120.00°
C94H88N20O19Sm2
C94H88N20O19Sm2
Dalton Transactions (2009) 12 2157-2169
a=16.8614(10)Å b=22.5574(10)Å c=24.3685(10)Å
α=90.00° β=94.169(10)° γ=90.00°
C51H42.5N16O23Sm
C51H42.5N16O23Sm
Dalton Transactions (2009) 12 2157-2169
a=14.1569(11)Å b=21.2008(16)Å c=21.2720(16)Å
α=90.00° β=107.7700(10)° γ=90.00°
C90H78Cl3N14O12Tb
C90H78Cl3N14O12Tb
Dalton Transactions (2009) 12 2157-2169
a=47.992(10)Å b=57.798(12)Å c=12.112(2)Å
α=90.00° β=90.00° γ=90.00°
C25H15F6N
C25H15F6N
RSC Adv. (2017) 7, 38 23515
a=8.6865(3)Å b=11.0532(4)Å c=22.5491(8)Å
α=90° β=95.493(3)° γ=90°
C36H28Cd2N6O8
C36H28Cd2N6O8
Dalton transactions (Cambridge, England : 2003) (2016) 45, 16 6983-6989
a=11.823(2)Å b=11.823(2)Å c=41.384(8)Å
α=90.00° β=90.00° γ=120.00°
(<i>S</i>,<i>R</i>,<i>Rp</i>)-<i>N</i>,<i>N</i>-Dimethyl-1-{2-[(1- phenylethyl)aminomethyl]ferrocenyl}ethanamine
C23H30FeN2
Acta Crystallographica Section E (2009) 65, 4 m432
a=7.20810(10)Å b=16.5546(3)Å c=17.6747(2)Å
α=90.00° β=90.00° γ=90.00°
(<i>E</i>)-<i>N</i>'-[(2-Hydroxynaphthalen-1-yl)methylidene]- 4-methylbenzohydrazide
C19H16N2O2
Acta Crystallographica Section E (2011) 67, 4 o964
a=11.014(2)Å b=15.487(2)Å c=9.1500(10)Å
α=90.00° β=93.503(3)° γ=90.00°
(9<i>S</i>,13<i>R</i>,14<i>S</i>)-7,8-Didehydro-4-(4-iodobenzyloxy)-3,7- dimethoxy-17-methylmorphinan-6-one monohydrate
C26H28INO4,H2O
Acta Crystallographica Section E (2010) 66, 11 o2817
a=8.9005(8)Å b=14.9221(14)Å c=9.2426(9)Å
α=90.00° β=91.432(2)° γ=90.00°
(<i>E</i>)-<i>N</i>'-[(2-Hydroxy-1-naphthalen-1-yl)methylidene]- 3-methylbenzohydrazide
C19H16N2O2
Acta Crystallographica Section E (2011) 67, 4 o965
a=7.1927(11)Å b=31.042(4)Å c=7.3557(11)Å
α=90.00° β=108.455(2)° γ=90.00°
(8<i>S</i>,9<i>S</i>,10<i>R</i>)-4-(4-Chlorobenzyloxy)-7,8-didehydro-3,7- dimethoxy-17-methylmorphinan-6-one monohydrate
C26H28ClNO4,H2O
Acta Crystallographica Section E (2011) 67, 5 o1190
a=8.8866(4)Å b=14.6386(7)Å c=9.1860(4)Å
α=90.00° β=91.6180(10)° γ=90.00°
5-Methyl-3,3-bis(4-methylpiperazin-1-yl)-1-[2-(4-methylpiperazin-1- yl)ethyl]indolin-2-one
C26H43N7O
Acta Crystallographica Section E (2012) 68, 6 o1855
a=15.9433(8)Å b=14.4097(6)Å c=12.5310(6)Å
α=90.00° β=108.774(3)° γ=90.00°
(9<i>S</i>,13<i>R</i>,14<i>S</i>)-7,8-Didehydro-4-(4-fluorobenzyloxy)-3,7- dimethoxy-17-methylmorphinan-6-one sesquihydrate
C26H28FNO4,1.5(H2O)
Acta Crystallographica Section E (2011) 67, 8 o1988
a=18.0155(3)Å b=7.67760(10)Å c=18.1506(4)Å
α=90.00° β=109.3240(10)° γ=90.00°
(7<i>R</i>,8<i>S</i>,9<i>S</i>,12<i>S</i>)- 1-(4-Chlorobenzyloxy)-13,14-didehydro-12-hydroxy- 2,13-dimethoxy-<i>N</i>-methylmorphinane
C26H30ClNO4
Acta Crystallographica Section E (2011) 67, 9 o2480
a=7.8073(9)Å b=9.7598(11)Å c=31.043(2)Å
α=90.00° β=90.00° γ=90.00°
(7<i>R</i>,8<i>S</i>,9<i>S</i>,12<i>S</i>)-1-Benzyloxy-13,14- didehydro-12-hydroxy-2,13-dimethoxy-<i>N</i>-methylmorphinane
C26H31NO4
Acta Crystallographica Section E (2011) 67, 10 o2662-o2663
a=7.7191(2)Å b=8.5100(2)Å c=9.9630(2)Å
α=79.9710(10)° β=67.6630(10)° γ=64.6050(10)°
C19H16O
C19H16O
The Journal of organic chemistry (2017) 82, 5 2523-2534
a=6.75819(13)Å b=8.55021(16)Å c=24.5163(5)Å
α=90° β=97.7995(19)° γ=90°
C28H26O
C28H26O
The Journal of organic chemistry (2018) 83, 8 4441-4454
a=9.9497(7)Å b=23.3460(12)Å c=10.3370(8)Å
α=90° β=117.278(9)° γ=90°
C31H25Cl
C31H25Cl
The Journal of organic chemistry (2018) 83, 8 4441-4454
a=9.90789(18)Å b=19.4213(4)Å c=11.7413(2)Å
α=90° β=90.2212(17)° γ=90°
C26H24OS
C26H24OS
The Journal of organic chemistry (2018) 83, 8 4441-4454
a=11.1052(4)Å b=10.7198(4)Å c=17.6163(6)Å
α=90° β=104.009(4)° γ=90°
C26H25O
C26H25O
The Journal of organic chemistry (2018) 83, 8 4441-4454
a=8.8859(6)Å b=9.9045(6)Å c=11.8557(6)Å
α=99.769(4)° β=96.190(5)° γ=109.258(6)°
C26H26O
C26H26O
The Journal of organic chemistry (2018) 83, 8 4441-4454
a=11.6446(4)Å b=7.3696(2)Å c=23.0316(8)Å
α=90° β=94.897(3)° γ=90°
C23H24O
C23H24O
The Journal of organic chemistry (2018) 83, 8 4441-4454
a=9.5076(6)Å b=10.1735(7)Å c=11.0649(6)Å
α=100.526(5)° β=108.648(5)° γ=114.007(6)°